These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28687750)

  • 1. 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.
    Guo X; Zheng H; Luo W; Zhang Q; Liu J; Yao K
    Sci Rep; 2017 Jul; 7(1):4859. PubMed ID: 28687750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.
    Wei F; Rong XX; Xie RY; Jia LT; Wang HY; Qin YJ; Chen L; Shen HF; Lin XL; Yang J; Yang S; Hao WC; Chen Y; Xiao SJ; Zhou HR; Lin TY; Chen YS; Sun Y; Yao KT; Xiao D
    Oncotarget; 2015 Oct; 6(33):35023-39. PubMed ID: 26418951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.
    Ren X; Ma W; Lu H; Yuan L; An L; Wang X; Cheng G; Zuo S
    Cancer Immunol Immunother; 2015 Dec; 64(12):1517-29. PubMed ID: 26386966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system.
    Yang T; Zhang W; Wang L; Xiao C; Wang L; Gong Y; Huang D; Guo B; Li Q; Xiang Y; Nan Y
    BMC Cancer; 2018 Oct; 18(1):984. PubMed ID: 30326865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
    Huo Q; Lv J; Zhang J; Huang H; Hu H; Zhao Y; Zhang X; Wang Y; Zhou Y; Qiu J; Ye Y; Huang A; Chen Y; Qin L; Qin D; Li P; Cai G
    Cytotherapy; 2023 Oct; 25(10):1037-1047. PubMed ID: 37436338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
    Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
    Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.
    Stern PL; Harrop R
    Cancer Immunol Immunother; 2017 Apr; 66(4):415-426. PubMed ID: 27757559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of latent membrane protein 2A chimeric antigen receptor-T cells and their lethal effects on nasopharyngeal carcinoma cells].
    Chen Y; Chen RJ; Huang XC; Tang GX; Kuai XW; Zhang MJ; Zhang DW; Tang Q; Zhu J; Feng ZQ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Dec; 53(12):925-930. PubMed ID: 30585005
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
    Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
    Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells.
    Schlimper C; Hombach AA; Abken H; Schmidt-Wolf IG
    Clin Dev Immunol; 2012; 2012():238924. PubMed ID: 22481963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
    Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo.
    Guo C; Dong E; Lai Q; Zhou S; Zhang G; Wu M; Yue X; Tao Y; Peng Y; Ali J; Lu Y; Fu Y; Lai W; Zhang Z; Ma F; Yao Y; Gou L; Yang H; Yang J
    MedComm (2020); 2020 Dec; 1(3):338-350. PubMed ID: 34766126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
    Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
    Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.
    Merker M; Pfirrmann V; Oelsner S; Fulda S; Klingebiel T; Wels WS; Bader P; Rettinger E
    Oncotarget; 2017 Sep; 8(39):66137-66153. PubMed ID: 29029499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment.
    Hung LVM; Ngo HT; Van Pham P
    Adv Exp Med Biol; 2020; 1292():113-130. PubMed ID: 32430854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.